|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 8,802,142: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 8,802,142, granted on August 5, 2014, to Eli Lilly and Company, covers a novel class of compounds with potential therapeutic applications, notably in oncology. This patent exemplifies strategic patenting in the pharmaceutical sector, aiming to protect chemical entities, their uses, and manufacturing methods. This analysis delves into the patent's scope and claims, evaluates its positioning within the broader patent landscape, and discusses implications for stakeholders.
What Is the Scope of U.S. Patent 8,802,142?
The patent primarily claims the chemical entities, their pharmacological uses, and methods for their synthesis. It broadly encompasses:
- Chemical compounds: Specific derivatives, including substituted heterocycles designed for therapeutic purposes.
- Uses: Particularly, as kinase inhibitors targeting certain pathways relevant to cancer treatment.
- Methods: Synthesis and formulation techniques for these compounds.
The scope strategically balances breadth with specificity, aiming to cover a wide chemical space while focusing on high-value therapeutic applications.
What Are the Key Claims of U.S. Patent 8,802,142?
1. Chemical Compound Claims
The patent explicitly claims a series of chemical structures characterized by particular core frameworks and substituents. Examples include:
| Claim Type |
Scope |
Details |
| Core Structure Claims |
Fundamental chemical backbone |
Substituted heterocycles, often including pyrimidine or quinazoline cores. |
| Substituted Derivatives |
Variations on core |
Substituents such as alkyl, alkoxy, halogens, or amino groups at specified positions. |
| Prodrug and Salt Forms |
Pharmacologically acceptable forms |
Amorphous, crystalline, or salt forms for enhanced stability or bioavailability. |
Patent Claims (Sample):
- Claim 1: A compound of formula (I), wherein the substituents satisfy the structure described in the claim, exhibiting kinase inhibitory activity.
- Claim 15: A pharmaceutical composition comprising a compound as claimed in Claim 1 and a pharmaceutically acceptable carrier.
2. Pharmacological Use Claims
These claims specify intended therapeutic applications, such as:
| Use Claim Type |
Description |
JURISDICTIONAL Note |
| Method of Treatment |
Use of compounds for inhibiting kinase activity |
Incorporates specific cancer types like non-small cell lung carcinoma. |
| Prophylactic and Therapeutic Uses |
Preventive or curative measures against tumors |
Emphasizes utility in targeted therapy. |
3. Manufacturing and Formulation Claims
Further claims cover methods for synthesizing the compounds and their formulations, including:
| Claim Type |
Focus |
Example |
| Synthesis Methods |
Routes with improved yield or selectivity |
Catalytic processes, purification steps. |
| Dosage Form Claims |
Tablets, capsules, injectable forms |
Specific excipients and stabilization techniques. |
Patent Landscape for Similar Drugs and Technologies
1. Major Competitors and Overlapping Patents
The therapeutic focus—kinase inhibition, especially targeting Epidermal Growth Factor Receptor (EGFR) and Fibroblast Growth Factor Receptor (FGFR) pathways—places this patent within a crowded landscape. Key overlaps include:
| Patent / Patent Family |
Assignee |
Target / Focus |
Filing Year |
Key Claims |
| US Patent 8,677,081 |
Novartis |
EGFR inhibitors |
2012 |
Structure and use claims similar to 8,802,142 |
| US Patent 8,866,372 |
AstraZeneca |
Cancer kinase inhibitors |
2013 |
Broad compounds with similar heterocyclic cores |
| WO 2011/075789 |
Pfizer |
FGFR inhibitors |
2010 |
Chemical scaffolds akin to those claimed in 8,802,142 |
2. Patent Ages and Trends
Most related patents filed between 2008-2014, reflecting a strategic window during the early years of targeted cancer therapies. The patent landscape is highly dynamic, with filings still ongoing, indicating continued R&D investments.
3. Geographical Patent Coverage
While this analysis centers on U.S. patents, similar patent families exist globally in jurisdictions like:
| Jurisdiction |
Patent Family Member |
Status |
Key Notes |
| Europe |
EP 2,435,267 |
Granted |
Similar chemical scope; potential for enforceability |
| China |
CN 102,830,892 |
Pending |
Expanding market presence |
How Does U.S. Patent 8,802,142 Fit in the Broader Landscape?
- Novelty and Non-Obviousness: The patent claims specific chemical modifications that distinguish them from prior art. Prior art references, such as earlier quinazoline derivatives, are acknowledged but differ sufficiently to avoid invalidity.
- Claim Breadth vs. Specificity: The patent balances broad chemical claims with narrower therapeutic use claims, providing robustness against design-arounds.
- Life Cycle and Patent Term: Filed around 2012 and granted in 2014, expiration can be expected around 2032-2034, depending on patent term adjustments and regulatory delays.
- Litigation and Challengers: No known litigations have challenged this patent to date, but disputes over similar kinase inhibitors are common.
Implications for the Industry
- For Innovators: The broad chemical coverage presents barriers for competitors developing similar compounds.
- For Generic Manufacturers: The narrowness of some claims might allow the development of alternative derivatives outside the patent scope.
- For Collaborators and Licensees: License agreements must negotiate rights aligned with the claims’ scope, especially in derivatives and uses.
Comparison of Key Aspects With Closely Related Patents
| Aspect |
U.S. Patent 8,802,142 |
Novartis US 8,677,081 |
AstraZeneca US 8,866,372 |
| Compound Core |
Quinazoline derivatives |
Quinazoline derivatives |
Benzimidazole derivatives |
| Indications |
Multiple cancers |
Lung and breast cancers |
Various solid tumors |
| Claim Breadth |
Broad structural and use claims |
Focused structural claims |
Compound and use claims |
| Filing Date |
2012 |
2010 |
2010 |
This analysis underscores the strategic positioning of the patent within the competitive landscape, balancing claims to proprietary chemistry and therapeutic utility.
Key Takeaways
- Patent Scope: U.S. Patent 8,802,142 claims a broad class of kinase inhibitor compounds with therapeutic applications in oncology.
- Claims: Encompass chemical structures, methods of use, and synthesis approaches, providing comprehensive protection.
- Landscape Positioning: Situated amid a suite of patents targeting similar kinase pathways, with competitors such as Novartis and AstraZeneca holding overlapping filings.
- Strategic Importance: The patent’s broad claims block competitors from developing similar compounds within its scope, supporting Lilly’s market position in targeted cancer therapies.
- Expiration and Enforcement: Anticipated around 2032–2034, with ongoing R&D and patent applications likely extending the competitive boundary.
FAQs
Q1: Are the claims in U.S. Patent 8,802,142 limited to specific compounds, or do they cover broad chemical classes?
The claims are broad, covering various substituted heterocyclic compounds, but with defined structural cores, balancing scope with specificity.
Q2: Does this patent cover only compounds, or does it include methods of treatment?
It includes both chemical compounds and methods of their therapeutic use, especially as kinase inhibitors.
Q3: How does the patent landscape for kinase inhibitors impact generic development?
Broad claims may inhibit generic manufacturers from developing similar compounds within the claimed chemical space, although narrow claim provisions or design-around strategies can facilitate non-infringing alternatives.
Q4: What are the main strategic benefits for Eli Lilly in holding this patent?
Protection of a novel chemical series, potential licensing opportunities, and exclusion of competitors from specific chemical and therapeutic claims.
Q5: How often are patents similar to 8,802,142 challenged or litigated?
While no known litigations exist for this particular patent, kinase inhibitor patents are commonly subject to patent disputes, emphasizing the need for continuous patent strategy and FTO analyses.
References
- U.S. Patent 8,802,142. Eli Lilly and Company. Granted August 5, 2014.
- Related Patents:
- Novartis US 8,677,081.
- AstraZeneca US 8,866,372.
- WO 2011/075789 (Pfizer).
- Patent Landscape Reports:
- "Kinase Inhibitor Patent Landscape," License Global, 2015.
- "Targeted Cancer Therapy Patents," World Patent Review, 2018.
Note: Continuous monitoring of patent filings, litigation, and regulatory developments is essential for comprehensive strategic planning in this domain.
More… ↓
⤷ Start Trial
|
